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Women of advanced maternal age (AMA, >34 years 
old) are at an increased risk of having an infant with 
a chromosome abnormality,[1] but only a minority of 
older South African women have access to genetic 
counselling and testing for such abnormalities during 
pregnancy.[2] These women face difficult choices relating to their risks 
and options. AMA in itself may cause anxiety for women, but the 
HIV/AIDS pandemic in South Africa complicates their predicament. 
In the antenatal genetic counselling clinics held at three academic 
hospitals in Johannesburg, the percentage of pregnant women who 
are HIV-positive is increasing.[3] For a pregnant HIV-positive woman 
to make fully informed decisions regarding her pregnancy and her 
reproductive choices, she needs to have a clear understanding of the 
impact of her HIV status on her own future health and that of her 
unborn infant.
HIV is a retrovirus that is usually transmitted through sexual 
contact, but it can also be transmitted vertically from mother to child 
during pregnancy, at birth and through breastmilk. In developing 
countries, HIV is most commonly transmitted by heterosexual 
contact and by mother-to-child transmission (MTCT).[4] The risk of 
MTCT depends on several factors, including maternal viral load and 
CD4 count, mode of parturition, and availability of antiretroviral 
treatment during pregnancy and delivery.[4] The type and regimen of 
antiretroviral therapy (ART) also influences the transmission rate.[5]
South Africa, with only 0.7% of the global population, has 17% of 
the HIV/AIDS burden.[6] As a result life expectancy has fallen from 
62 years in 1992 to 50.5 years in 2007.[7] However, it has been difficult 
to estimate the number of infected adults accurately. According to 
data extrapolated from antenatal surveys, the HIV prevalence rate 
rose from 1% in 1990 to 25% in 2000,[3,8] and population incidence 
estimates range between 10.4 and 14.2%.[3]
According to Dabis and Ekpini,[8] the MTCT rate in Africa ranges 
from 25% to 45%, with transmission dependent on maternal viral 
load and length of breastfeeding. The higher the maternal viral load, 
the greater the risk of intra-uterine and intrapartum transmission. 
Worldwide, approximately 600 000 infants are infected with HIV 
via their mothers each year.[9] The infection accounted for 7.7% of all 
deaths of under 5-year-olds in sub-Saharan Africa in 1999, compared 
with 2% in 1990.[10] In Africa there is more rapid progression from 
HIV to AIDS than in industrialised countries, as a result of poor 
baseline health, poor nutrition and ill-equipped health services.[8]
The World Health Organization[11] has suggested the following 
strategies to reduce MTCT: prevention of new infections in adults; 
prevention of unwanted pregnancies; prevention of MTCT; provision 
of antiretroviral treatment to pregnant women in the peripartum 
period and to the neonate; and provision of care and support to HIV-
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more HIV-negative patients (79/183, 43.2%) than those who were HIV-positive (6/44, 13.6%) had amniocentesis performed for fetal 
diagnosis. Most of the interviewed women (12/15, 80.0%) understood the severity of HIV infection, 5 (33.3%) considered termination 
of pregnancy based on the transmission risk, and 4 (26.7%) would have requested amniocentesis and prenatal diagnosis if they had been 
HIV-negative.
Conclusion. Decision-making regarding prenatal genetic diagnosis is influenced by HIV status among older women. Effective access to 
highly active antiretroviral therapy throughout pregnancy would make decision-making easier for these women.
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Prenatal diagnosis has been available for older women at risk 
for chromosomal defects in their infants for several decades. 
Professor Trefor Jenkins was instrumental in initiating this service 
in Johannesburg at both the laboratory and genetic counselling 
levels. He subscribed to the philosophy of freedom of choice and 
informed decision making in this situation and supported couples 
in their decisions. The HIV epidemic brings in a new factor for the 
older at-risk woman who is HIV-positive, and this article reports on 
a study on this topic.
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infected women, their infants and their families.[8] Ideally pregnant 
women should be on a multi-drug regimen to lower the viral load, 
thereby reducing the risk of HIV transmission to the fetus. In 
developed countries the risk of MTCT has fallen from approximately 
30% to less than 5% as a result of prevention strategies. [12] This 
risk can be reduced to 1.2% when highly active antiretroviral 
therapy (HAART) is administered.[5] In resource-constrained settings, 
inadequate finances and infrastructure may limit the practicality 
of implementing prevention programmes. However, the use of 
single-dose regimens may be worth considering because a 47% 
reduction in the 3-month transmission rate from mother to child was 
observed in the Ugandan HIVNET 012 trial,[13] with only 13.1% of 
infants becoming HIV-positive. This treatment programme is viable 
and cost-effective, and because it is a once-off treatment at birth, 
adherence is good. Problems with this treatment may arise if HIV 
resistance to nevirapine occurs after the single dose.
Older maternal age is associated with an increased risk of having 
an infant with a chromosome abnormality, especially trisomies,[1] the 
most common being Down syndrome (DS), which occurred in about 
2.1/1 000 (1/476) births in one South African rural area. [14] Genetic 
counselling should be offered to all pregnant women of AMA, and 
age-related risks (which increase exponentially with age) of having a 
child with a chromosomal abnormality, as well as options for prenatal 
testing and selective termination of pregnancy if a fetal abnormality 
is detected, should be discussed. Decisions should be made according 
to the social circumstances and cultural and religious beliefs of the 
patient.[15] In South Africa, pregnant women aged 35 years or older 
are considered to be of AMA, as recommended in the Department 
of Health Policy Guidelines,[16] and 15.1% of women are in this 
category. [17]
The options for prenatal testing in any one referral hospital depend 
on the stage of the pregnancy and the practices of the hospital 
where the antenatal clinic is held. Chorionic villus sampling (CVS) 
is only available at Chris Hani Baragwanath Academic Hospital, 
Johannesburg, while amniocentesis for prenatal genetic testing is 
performed at all three academic hospitals in Johannesburg. Both 
techniques are invasive and carry a small risk of spontaneous 
abortion. This risk varies depending on the skill of the operator, but 
even with experience the risk of miscarriage after CVS is given as 1 - 
3%,[18] and that after amniocentesis is 0.5 - 1%.[2]
The risk of having an infant with a chromosomal disorder 
associated with AMA is relatively low compared with the risk of 
HIV transmission from an infected mother to the infant when 
HAART is not available. Ignoring the risk of HIV transmission, 
which is as high as 30% without any antiretroviral treatment, and is 
13.1% even with nevirapine treatment (given prior to birth, plus a 
dose given to the neonate shortly after birth), is incompatible with 
appropriate, logical and ethical patient care. A genetic condition with 
a risk of transmission as high as 13.1% and as poor a prognosis as 
HIV in infants would warrant the option of selective termination of 
pregnancy.
Few studies examining the risk of MTCT associated with second-
trimester amniocentesis have been conducted, but a fourfold 
increase in the third trimester has been documented by Tess et al.[19] 
Another study[20] showed that amniocentesis without antiretroviral 
cover resulted in an increase in the transmission rate. However, 
use of HAART appears to reduce the risk of MTCT during 
amniocentesis, and the viral load in the amniotic fluid was found 
to be undetectable in women using this therapy, even when it was 
detectable in maternal blood.[21] It is therefore inferred from these 
studies that second-trimester amniocentesis carries an inherent 
risk of vertical transmission from mother to fetus, but the exact risk 
is not known. As HIV is present in the amniotic fluid of untreated 
infected women,[22] it would be unethical to offer an HIV-positive 
woman a second-trimester amniocentesis without informing her of 
the transmission risks.
Raising anxiety about HIV infection alters the structure, nature 
and outcome of the genetic counselling session. The counsellee is 
faced with negative information, and it may be difficult for her to 
consider her prenatal diagnosis options optimally. She may need 
time to internalise the information, and then her interpretation of 
the information needs to be explored, with issues of social isolation, 
stigmatisation and low self-worth being dealt with before she makes 
decisions.[23]
Ojectives
To investigate, in pregnant women of AMA who had been tested for 
HIV status, the following: the uptake of amniocentesis for prenatal 
genetic diagnosis; the choices made regarding fetal genetic testing 
and termination of pregnancy; knowledge of maternal-infant HIV 
transmission; and perceptions of the impact of their HIV status on 
their decision-making.
Methods
The setting of the study was the genetic counselling clinics at three 
Johannesburg academic hospitals, Johannesburg Hospital (now called 
Charlotte Maxeke Johannesburg Academic Hospital), Coronation 
Hospital (now Rahima Moosa Mother and Child Hospital) and 
Chris Hani Baragwanath Academic Hospital, one Pretoria academic 
hospital (Kalafong), and one private hospital in Johannesburg 
(Donald Gordon Medical Centre). All the participating women were 
drawn from the patients attending these hospitals.
 There were two parts to this study. The first involved documenting 
(retrospectively) and comparing over two 6-month periods (February 
- July 2003 and February - July 2004) data on the numbers of pregnant 
women counselled for AMA (>34 years) and their ages, HIV status, 
and decisions regarding prenatal genetic testing. The second part, 
involving interviews with HIV-positive pregnant women during the 
second time period, investigated their knowledge regarding MTCT 
and their prenatal diagnosis decisions.
Records for all the women who attended the genetic counselling 
clinics over the two 6-month periods were sought in the filing system 
of the Division of Human Genetics, National Health Laboratory 
Service (NHLS) and University of the Witwatersrand, and 350 files 
were found. In the 2003 sample, 169 women were counselled, an 
average of 28 per month, and in the 2004 sample, 181 women were 
seen, averaging 30 per month. The majority of women (343/350, 
98.0%) were seen at the three academic hospitals in Johannesburg. 
The remaining 7 women (2.0%) were either from Kalafong Hospital 
or the Donald Gordon Medical Centre. The following details were 
collected (using a check-list compiled by the first author, JSB): date of 
birth, occupation, address, marital status, parity, obstetric and family 
history, clinic attended, date of ultrasound examination, duration of 
pregnancy, HIV status, decisions surrounding amniocentesis and 
termination of pregnancy, and notes made by the counsellor on the 
counselling session. This information was documented in an Excel 
spreadsheet.
The research instrument for the 2004 interview sample was a 
schedule of questions developed by one of the authors (JSB) in 
consultation with a clinical geneticist (ALC). This schedule comprised 
14 questions investigating the participants’ attitudes and knowledge 
regarding AMA and chromosome abnormalities; HIV, HIV testing 
and MTCT in pregnancy; and the options of prenatal genetic testing 
and termination of pregnancy, based on the fetal abnormalities and/
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or the MTCT risk. Interviews were conducted by the doctors and 
genetic counsellors of the Division of Human Genetics, NHLS, and 
the completed schedules were given to the researcher (JSB).
The data from the completed check-lists and questionnaires were 
analysed to provide the results of the study. Stata Release version 8 
and Fisher’s exact test were used to undertake the statistical analysis. 
All tests were two-tailed, and p-values of <0.05 were considered 
significant.
Ethics approval for the project was granted by the Committee for 
Research on Human Subjects of the University of the Witwatersrand 
on 29 January 2004.
Results
The subjects were pregnant women of AMA, residing in the urban 
areas of Johannesburg. They were from various educational and 
socioeconomic backgrounds. The majority of patients were black 
Africans, but there were also a few patients of mixed ancestry and 
of Caucasian origin. The biggest single group of women (59.4%, 
173/350) were at 16 - 20 weeks’ gestation at the time of ascertainment 
(range 10 - 24 weeks). HIV testing was carried out at the antenatal 
clinics, but results were available for only 31.4% of the patients 
(Table 1).
Altogether 110/350 (31.4%) women chose to have prenatal genetic 
testing. However, a significantly greater number of women aged 
40 years and older (43/107, 40.2%) had testing compared with those 
aged between 35 and 39 years (67/243, 27.6%) (p=0.024).
There was a statistically significant increase in the number of patients 
whose HIV status was known in 2004 compared with those seen in 
2003 (p=0.01). Of the 169 women counselled in 2003, the HIV status 
was known for 98 (58%), while in the 2004 group, the HIV status of 
129/181 women (71.3%) was known. The results of HIV testing are 
shown in Table 2.
Although the HIV status of more women was known in the 
6 months of 2004 compared with the 6 months of 2003, there was no 
statistically significant increase in the number of women who tested 
HIV-positive in the 2003 group (15/98, 15.3%) compared with the 
2004 group (29/129, 22.5%) (p=0.235).
Combining the data from both 6-month study groups, 79/183 
HIV-negative women (43.2%) and 6/44 HIV-positive women (13.6%) 
chose to have prenatal testing (Table 3). There was therefore a 
highly significant difference in uptake of amniocentesis, with the 
HIV-negative women more likely to have prenatal diagnosis for 
chromosome analysis than the HIV-positive women (p<0.001). A 
total of 110 amniocenteses were performed (31.4%), and 25 (22.7%) 
of these were on women of unknown HIV status.
No significant difference could be established between uptake 
of amniocentesis when the genetic counselling was provided by a 
medical geneticist (uptake 21/55, 38.2%) or a genetic counsellor/
genetic nurse (uptake 89/206, 43.2%) (p=0.269).
In the second part of the study, a sub-sample of the participants in 
the 2004 sample who were HIV-positive (29/181, 16%) were invited 
to participate in interviews. Altogether 29 women were approached 
and 15 (51.7%) participated. Reasons for non-participation included 
fear of disclosure, leaving the clinic before the session was completed, 
and lack of available translators. Since this sample was small, the 
results only suggest trends.
Most of the women (12/15, 80%) stated that their pregnancy was 
unplanned, and few (3/15, 20%) were aware of their age-related risks. 
Also, a small group of women (3/15, 20%) said that they had not been 
counselled regarding the risks of MTCT. However, 12/15 women 
(80%) reported being advised concerning avoidance of breastfeeding. 
Ten women (67%) remembered being told about the value of taking 
nevirapine at the onset of labour, but not all the women clearly 
understood how this affected the infant’s risk of infection and 
only half (8/15, 53.3%) knew that a risk of the child being infected 
Table 2. HIV status of women of AMA attending the genetic clinics in 2003 and 2004
AMA women
2003 2004
n % of total % of known HIV status n % of total % of known HIV status
HIV-negative 83 49.1 84.7 100 55.2 77.5
HIV-positive 15 8.9 15.3 29 16.0 22.5
Total known status 98 58.0   129 71.3  
Unknown status 71 42.0   52 28.7  
Total, N 169     181    
AMA = advanced maternal age.
Table 3. Rates of amniocentesis in women who were HIV-negative, HIV-positive or of unknown status (N=350)
Amniocentesis uptake
n/N (%)
HIV-negative HIV-positive HIV unknown Total
2003 40/83 (48.2) 2/15 (13.3) 16/44 (36.4) 58/169 (34.3)
2004 39/100 (39.0) 4/29 (13.8) 9/52 (17.3) 52/181 (28.7)
Total, N 79/183 (43.2) 6/44 (13.4) 25/96 (20) 110/350 (31.4)
Table 1. HIV testing in women of advanced maternal age who 
attended the genetic counselling clinics
Hospital
HIV testing
n (%)
No testing
n (%)
Total
N
Chris Hani Baragwanath 61 (36.1) 108 (63.9) 169
Charlotte Maxeke 28 (28.3) 71 (71.7) 99
Rahima Moosa 20 (26.7) 55 (73.3) 75
Other 1 (14.3) 6 (85.7) 7
Total, N 110 (31.4) 240 (68.6) 350
Ethical, psychosocial and anthropological
1030  December 2013, Vol. 103, No. 12 (Suppl 1)  SAMJ
remained, but that it was reduced. Four women (26.7%) thought that 
there was no risk of MTCT when nevirapine was used perinatally, 
and 3 others had misunderstood the use of nevirapine. Nine of the 
women (60%) stated that they had told their partners about their 
HIV-positive status, and 5 (33.3%) said that their partners had also 
been tested.
With regard to prenatal genetic testing, decisions varied: 4 
women (26.7%) said that they would have requested testing if they 
had not been HIV-positive, 2 (13.3%) would have requested it if 
antiretroviral cover was readily provided, and 3 (20%) said they 
would have requested testing regardless of HIV status or availability 
of antiretroviral prophylaxis. However, 5 women (33.3%) said they 
would not have wanted testing even if they had been HIV-negative. 
One woman (6.7%) requested termination of pregnancy (without 
testing) and was referred to the gynaecology outpatients department 
for further management.
Pregnant women who are HIV-positive have the option of selective 
termination of pregnancy up to 20 weeks’ gestation, because of the 
risk of MTCT during pregnancy and birth.[24] Eight (53.3%) of the 
15 women said that they had been advised about this risk, but only 
2 (13.3%) remembered being told about the option of termination. 
Of the 15 women, 5 (33.3%) said they would consider termination, 6 
(40%) said they would not consider this option, and 4 (26.7%) were 
too far advanced in their pregnancies to be offered the procedure. 
Of the 10 women (66.7%) who were either too late to be offered 
termination or who refused it, 5 (50%) did not properly understand 
the risk of MTCT.
Discussion
In a 2003 South African survey[3] the prevalence of HIV was 198/1 000 
(19.8%) in women aged 35 - 39 years and 172/1 000 (17.2%) in 
women aged over 40 years. The prevalence in the present study 
corresponds with these findings.
There was a statistically significant association (p<0.001) between 
HIV status and amniocentesis uptake, and HIV-positive status 
appeared to play a role in deterring older women from undergoing 
prenatal testing. The risk of MTCT associated with invasive testing is 
therefore a significant factor in decision-making regarding prenatal 
genetic testing in older women. However, other factors may have 
included the characteristics of the women, such as age-related issues 
(more of the older than the younger AMA women could have been 
HIV-positive, although this is somewhat unlikely), as well as the 
associated DS risks. Other factors identified in South African studies 
that may influence the uptake or rejection of prenatal testing include 
religious convictions, poor obstetric history, fear that the procedure 
will result in miscarriage,[2] and a limited understanding of the 
implications of a diagnosis of DS.[25] In Australia, women in public 
sector hospitals, who are generally of low socioeconomic status, are 
less likely to have amniocentesis than those in private hospitals,[26] 
suggesting that the former group may be less empowered to make 
decisions.
The fact that the older women (>39 years of age) in the present 
study requested prenatal testing significantly more often than the 
younger women (35 - 39 years) suggests that the women appeared 
to have an appropriate understanding of their age-related risks. 
Similarly, those counselled about the risk of MTCT acted according 
to their risk status.
Prophylactic treatment for HIV-positive pregnant women 
undergoing second-trimester amniocentesis was better established 
in 2004 than in 2003. Nevertheless, 2 (13.3%) of the 15 women 
participating in the interviews said that they would have considered 
amniocentesis if antiretroviral cover was readily provided, suggesting 
that some patients were not confident that the service would be 
available. From April 2013 South Africa adopted HAART for all 
HIV-positive pregnant women, regardless of CD4 count, as official 
policy. This development may lead to an increase in the uptake of 
amniocentesis in future.
Only 2 (13.3%) of the interviewed women remembered being 
told about the option of pregnancy termination based on the risk of 
MTCT, although at the time it was antenatal clinic policy to offer this 
procedure to HIV-positive pregnant women up to 20 weeks’ gestation. 
In practice, termination may only be offered to at-risk women at 
<12 weeks’ gestation (personal communication, Dr R Adams, 2013), 
and most of the women in the present study were more advanced. 
Other reasons for this reported lack of knowledge are not clear. 
However, women who have just been informed that they are HIV-
positive may be overwhelmed by the result, and may not assimilate all 
the information offered. In addition, HIV counsellors and antenatal 
clinic nurses may not be fully informed about this option, or they 
may have personal and moral objections to termination and therefore 
refrain from discussing it with the patient. In the small sample 
interviewed, 5 women (33.3%) considered termination of pregnancy, 
based on MTCT, after genetic counselling, but only 1 patient in the 
2003 group, and another in 2004, requested the procedure.
When the risk of HIV transmission to the fetus with and without 
perinatal antiretroviral prophylaxis was discussed in the interviews, 
a third of the women did not have a proper understanding of 
transmission of the virus. Unless women are very clear about the 
risks of HIV transmission to the fetus, they are not able to make 
fully informed decisions on termination or prenatal diagnosis, or to 
act appropriately. However, the health education process involves a 
level of health literacy, and the concepts are traditionally difficult to 
convey in the setting of prenatal genetic testing.[27] Furthermore, the 
study was conducted at a time of official denialism, stigmatisation 
of affected people, and limited public understanding about the 
nature and transmission of the virus (these factors may also have 
contributed to the relatively low uptake of HIV testing among the 
patients in the present study). Now that the condition is more openly 
acknowledged and managed, the situation should be different.
Initially nevirapine was usually given before amniocentesis, 
although a standard policy was not in place during the study period 
at any of the hospitals where genetic counselling took place. There 
is some uncertainty regarding the risk of drug resistance after 
administration of a single dose, and the consequent effectiveness 
of perinatal nevirapine prophylaxis to reduce MTCT.[28] Different 
policies for ART in pregnancy therefore existed at the three academic 
hospitals where genetic counselling was offered.
Although this study was carried out some years ago, when the 
management of HIV was somewhat different, it throws light on what 
can happen in under-resourced settings and provides a baseline from 
which to assess women’s understanding of MTCT and risks to the 
fetus, as well as the factors involved in their attitudes to genetic testing 
and prenatal diagnosis.
Conclusion
This study showed that HIV-positive older women (>34 years) were 
significantly less likely to accept prenatal testing for chromosome 
abnormalities than women of the same age who were HIV-negative. 
Also, older women (>39 years) in the AMA group were significantly 
more likely to request amniocentesis than younger women (35 - 
39 years) in this group.
The small sample of women interviewed in the present study 
perceived the impact of their HIV status as serious for themselves 
and their infants. Several knew of the MTCT risk, and that ART 
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is required before amniocentesis. These trends were observed, but 
need to be confirmed by further studies with larger samples and 
after effective HAART programmes for all affected pregnant women 
have been introduced. It can, however, be inferred from the data 
that although the HIV-positive AMA women were aware of the 
seriousness of HIV, many were unaware of the option of termination 
of pregnancy for the MTCT risk, and of those few who considered 
termination, very few requested the procedure.
The risk of a child having a chromosome abnormality ranges from 
0.5% (35-year-old mother) to 12.5% (49-year-old mother).[29] These 
risks cannot be presented in isolation, while disregarding the greater 
risks and serious implications of HIV infection, in a South African 
setting. This approach does not suggest that AMA counselling be 
neglected, as the risks remain significant. It is therefore important 
that the new policy of offering HAART to all HIV-positive pregnant 
women is effectively implemented, so that the risk of MTCT during 
invasive testing is reduced and decision-making for older women in 
this situation simplified.
Some non-invasive first-trimester combination screening for 
prenatal diagnosis, and refining of DS risks based on the results, is 
offered in a few South African hospitals. These procedures are not 
available to the majority of women at risk, and will probably not 
be for some time to come, as they are costly and the logistics are 
complex. These women will therefore probably continue to use the 
second-trimester amniocentesis service and continue to be given age-
related risks only. However, infant mortality rates have recently fallen 
dramatically in the Western Cape Province of South Africa as a result 
of the introduction of an effective MTCT prevention programme.[30] If 
the risks of vertical transmission of HIV from mother to child can be 
reduced throughout the country, if these risks become less significant 
than the risks associated with increasing maternal age, and if in the 
future first-trimester screening could be offered to women of all ages 
(as is recommended in the Netherlands[31]) so that the DS risks can be 
refined, invasive testing for chromosome abnormalities will become 
a more viable and relatively safe option for women who are HIV-
positive, of AMA and at increased risk.
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